



What is claimed is:

1. A compound of the formula

5



R_a denotes a hydrogen atom or a methyl group,

10

R_b denotes a phenyl, benzyl or 1-phenylethyl group, wherein the phenyl core is substituted in each case by the groups R₁ to R₃, whilst

15

R₁ and R₂, which may be identical or different, each denote a hydrogen, fluorine, chlorine, bromine or iodine atom,

a methyl, ethyl, hydroxy, methoxy, ethoxy, amino, cyano, vinyl or ethynyl group,

an aryl, aryloxy, arylmethyl or arylmethoxy group,

20

a methyl or methoxy group substituted by 1 to 3 fluorine atoms or

R₁ together with R₂, if they are bound to adjacent carbon atoms, denote a -CH=CH-CH=CH-, -CH=CH-NH- or -CH=N-NH- group and

R_3 denotes a hydrogen, fluorine, chlorine or bromine atom,

R_c denotes a hydrogen atom or a methyl group,

5

X denotes a methyne group substituted by a cyano group or a nitrogen atom,

A denotes a 1,1- or 1,2-vinylene group, each of which may be substituted by one or two methyl groups or by a trifluoromethyl group,

10

an ethynylene group, or

a 1,3-butadien-1,4-ylene group optionally substituted by a methyl or trifluoromethyl group,

15

B denotes a hydrogen atom or a C_{1-4} -alkyl group, a methyl group substituted by 1 to 3 fluorine atoms, an ethyl group substituted by 1 to 5 fluorine atoms, a C_{1-4} -alkylcarbonyl, carboxy, C_{1-4} -alkoxycarbonyl, aminocarbonyl, C_{1-4} -alkylaminocarbonyl, di- $(C_{1-4}$ -alkyl)-aminocarbonyl, pyrrolidinocarbonyl, piperidinocarbonyl, morpholinocarbonyl or a 4- $(C_{1-4}$ -alkyl)-piperazinocarbonyl group, or

20

a C_{1-4} -alkyl group substituted by the group R_4 , whilst

R_4 denotes a C_{1-4} -alkoxy group,

25

an amino group substituted by two C_{1-4} -alkyl groups, wherein the alkyl groups may be identical or different and each alkyl moiety may be substituted from position 2 by a C_{1-4} -alkoxy- or di- $(C_{1-4}$ -alkyl)-amino group or by a 4- to 7-membered alkyleneimino group, whilst in the above-mentioned 6- to 7-membered alkyleneimino groups in each case a methylene group may be replaced in the 4-position by an oxygen or sulphur atom, by a

30 sulphinyl, sulphonyl or N- $(C_{1-4}$ -alkyl)-imino group,

a 4- to 7-membered alkyleneimino group optionally substituted by 1 to 4 methyl groups,

a 6- to 7-membered alkyleneimino group optionally substituted by 1 or 2 methyl groups,
wherein in each case a methylene group in the 4-position is replaced by an oxygen or
5 sulphur atom, by a sulphinyl, sulphonyl or N-(C₁₋₂-alkyl)-imino group, or

an imidazolyl group optionally substituted by 1 to 3 methyl groups,

10 C denotes a C₁₋₆-alkylene group, a -O-C₁₋₆-alkylene group, whilst the alkylene moiety is linked to the group D, or an oxygen atom, which may not be linked to a nitrogen atom of the group D, and

D denotes a pyrrolidino group in which the two hydrogen atoms are replaced in the 2-
position by a group E, wherein

15 E denotes a -CH₂-O-CO-CH₂-, -CH₂CH₂-O-CO-, -CH₂-O-CO-CH₂CH₂-, -CH₂CH₂-O-CO-CH₂- or -CH₂CH₂CH₂-O-CO- bridge optionally substituted by one or two C₁₋₂-alkyl groups,

20 a pyrrolidino group in which the two hydrogen atoms are replaced in the 3-position by a group F, wherein

F denotes a -O-CO-CH₂CH₂-, -CH₂-O-CO-CH₂-, -CH₂CH₂-O-CO-, -O-CO-CH₂CH₂CH₂-,
-CH₂-O-CO-CH₂CH₂-, -CH₂CH₂-O-CO-CH₂-, -CH₂CH₂CH₂-O-CO-, -O-CO-
25 CH₂-NR₅-CH₂-, -CH₂-O-CO-CH₂-NR₅-, -O-CO-CH₂-O-CH₂- or -CH₂-O-CO-CH₂-O-
bridge optionally substituted by one or two C₁₋₂-alkyl groups, whilst

R₅ denotes a hydrogen atom or a C₁₋₄-alkyl group,

30 a piperidino or hexahydroazepino group, wherein the two hydrogen atoms are replaced in the 2-position by a group E, where E is as hereinbefore defined,

a piperidino or hexahydroazepino group, wherein in each case the two hydrogen atoms in the 3-position or in the 4-position are replaced by a group F, where F is as hereinbefore defined,

5

a piperazino- or 4-(C₁₋₄-alkyl)-piperazino group, wherein the two hydrogen atoms in the 2-position or in the 3-position of the piperazino ring are replaced by a group E, where E is as hereinbefore defined,

10

a pyrrolidino or piperidino group, wherein two vicinal hydrogen atoms are replaced by a -O-CO-CH₂- -CH₂-O-CO-, -O-CO-CH₂CH₂-, -CH₂-O-CO-CH₂-, -CH₂CH₂-O-CO-, -O-CO-CH₂-NR₅- or -O-CO-CH₂-O- bridge optionally substituted by one or two C₁₋₂-alkyl groups, whilst R₅ is as hereinbefore defined and the heteroatoms of the above-mentioned bridges are not bound to the 2- or 5-position of the pyrrolidino ring and are not bound to the 2- or 6-position of the piperidino ring,

15

a piperazino or 4-(C₁₋₄-alkyl)-piperazino group, wherein a hydrogen atom in the 2-position together with a hydrogen atom in the 3-position of the piperazino ring are replaced by a -CH₂-O-CO-CH₂- or -CH₂CH₂-O-CO- bridge optionally substituted by one or two C₁₋₂-alkyl groups,

20

a piperazino group in which a hydrogen atom in the 3-position together with the hydrogen atom in the 4-position are replaced by a -CO-O-CH₂CH₂- or -CH₂-O-CO-CH₂- bridge optionally substituted by one or two C₁₋₂-alkyl groups, whilst in each case the left-hand end of the above-mentioned bridges is bound to the 3-position of the piperazino ring,

25

a pyrrolidino, piperidino or hexahydroazepino group substituted by the group R₆, wherein

R₆ denotes a 2-oxo-tetrahydrofuran-yl, 2-oxo-tetrahydropyran-yl, 2-oxo-1,4-dioxan-yl or 2-oxo-4-(C₁₋₄-alkyl)-morpholin-yl group optionally substituted by one or two C₁₋₂-alkyl groups,

5 a pyrrolidino group substituted in the 3-position by a 2-oxo-morpholino group, whilst the 2-oxo-morpholino group may be substituted by one or two C₁₋₂-alkyl groups,

a piperidino or hexahydroazepino group substituted in the 3- or 4-position by a 2-oxo-morpholino group, whilst the 2-oxo-morpholino group may be substituted by one or two
10 C₁₋₂-alkyl groups,

a 4-(C₁₋₄-alkyl)-piperazino or 4-(C₁₋₄-alkyl)-homopiperazino group substituted at a ring nitrogen atom by R₆, wherein R₆ is as hereinbefore defined,

15 a piperazino or homopiperazino group substituted in the 4- position by the group R₇, wherein

R₇ denotes a 2-oxo-tetrahydrofuran-3-yl, 2-oxo-tetrahydrofuran-4-yl, 2-oxo-tetrahydropyran-3-yl, 2-oxo-tetrahydropyran-4-yl or 2-oxo-tetrahydropyran-5-yl group
20 optionally substituted by one or two C₁₋₂-alkyl groups,

a pyrrolidino group substituted in the 3-position by a (R₅NR₇)-, R₇O-, R₇S-, R₇SO- or R₇SO₂- group, whilst R₅ and R₇ are as hereinbefore defined,

25 a piperidino or hexahydroazepino group substituted in the 3- or 4-position by a (R₅NR₇)-, R₇O-, R₇S-, R₇SO- or R₇SO₂- group, wherein R₅ and R₇ are as hereinbefore defined,

a pyrrolidino, piperidino or hexahydroazepino group substituted by a R₆-C₁₋₄-alkyl-,
30 (R₅NR₇)-C₁₋₄-alkyl-, R₇O-C₁₋₄-

alkyl-, R₇S-C₁₋₄-alkyl-, R₇SO-C₁₋₄-alkyl-, R₇SO₂-C₁₋₄-alkyl- or (R₅NR₇)-CO- group, wherein R₅ to R₇ are as hereinbefore defined,

a pyrrolidino group substituted in the 3-position by a R₆-CO-NR₄, R₆-C₁₋₄-alkylene-CONR₄, (R₅NR₇)-C₁₋₄-alkylene-CONR₅, R₇O-C₁₋₄-alkylene-CONR₅, R₇S-C₁₋₄-alkylene-CONR₅, R₇SO-C₁₋₄-alkylene-CONR₅, R₇SO₂-C₁₋₄-alkylene-CONR₅, 2-oxo-morpholino-C₁₋₄-alkylene-CONR₅, R₆-C₁₋₄-alkylene-Y or C₂₋₄-alkyl-Y group, whilst the C₂₋₄-alkyl moiety of the C₂₋₄-alkyl-Y group is substituted in each case from position 2 by a (R₅NR₇)-, R₇O-, R₇S-, R₇SO- or R₇SO₂- group and the 2-oxo-morpholino moiety may be substituted by one or two C₁₋₂-alkyl groups, wherein

R₅ to R₇ are as hereinbefore defined and

Y denotes an oxygen or sulphur atom, an imino, N-(C₁₋₄-alkyl)-imino, sulphinyl or sulphonyl group,

a piperidino- or hexahydroazepino group substituted in the 3- or 4-position by a R₆-CO-NR₅, R₆-C₁₋₄-alkylene-CONR₅, (R₅NR₇)-C₁₋₄-alkylene-CONR₅, R₇O-C₁₋₄-alkylene-CONR₅, R₇S-C₁₋₄-alkylene-CONR₅, R₇SO-C₁₋₄-alkylene-CONR₅, R₇SO₂-C₁₋₄-alkylene-CONR₅, 2-oxo-morpholino-C₁₋₄-alkylene-CONR₅, R₆-C₁₋₄-alkylene-Y or C₂₋₄-alkyl-Y group, wherein Y is as hereinbefore defined, the 2-oxo-morpholino moiety may be substituted by one or two C₁₋₂-alkyl groups and the C₂₋₄-alkyl moiety of the C₂₋₄-alkyl-Y group is substituted in each case from position 2 by a (R₅NR₇)-, R₇O-, R₇S-, R₇SO- or R₇SO₂- group, whilst R₅ to R₇ are as hereinbefore defined,

25

a 4-(C₁₋₄-alkyl)-piperazino or 4-(C₁₋₄-alkyl)-homopiperazino group substituted at a ring nitrogen atom by a R₆-C₁₋₄-alkyl-, (R₅NR₇)-C₁₋₄-alkyl-, R₇O-C₁₋₄-alkyl-, R₇S-C₁₋₄-alkyl-, R₇SO-C₁₋₄-alkyl-, R₇SO₂-C₁₋₄-alkyl- or R₅NR₇-CO- group, wherein R₅ to R₇ are as hereinbefore defined,

30

a piperazino or homopiperazino group substituted in the 4- position by a R_6 - C_{1-4} -alkyl-, R_6 -CO-, R_6 - C_{1-4} -alkylene-CO-, (R_5NR_7) - C_{1-4} -alkylene-CO-, R_7O - C_{1-4} -alkylene-CO-, R_7S - C_{1-4} -alkylene-CO-, R_7SO - C_{1-4} -alkylene-CO- or R_7SO_2 - C_{1-4} -alkylene-CO- group, wherein R_5 to R_7 are as hereinbefore defined,

5

a piperazino or homopiperazino group substituted in the 4- position by a C_{2-4} -alkyl group, wherein the C_{2-4} -alkyl group is substituted in each case from position 2 by an (R_5NR_7) -, R_7O -, R_7S -, R_7SO - or R_7SO_2 - group, whilst R_5 and R_7 are as hereinbefore defined,

10 a pyrrolidino, piperidino- or hexahydroazepino group substituted by a 2-oxo-morpholino- C_{1-4} -alkyl group, wherein the 2-oxo-morpholino moiety may be substituted by one or two C_{1-2} -alkyl groups,

15 a pyrrolidino group, substituted in the 3-position by a C_{2-4} -alkyl-Y group, wherein Y is as hereinbefore defined and the C_{2-4} -alkyl moiety of the C_{2-4} -alkyl-Y group is substituted in each case from position 2 by a 2-oxo-morpholino group optionally substituted by one or two C_{1-2} -alkyl groups,

20 a piperidino or hexahydroazepino group substituted in the 3- or 4-position by a C_{2-4} -alkyl-Y group, wherein Y is as hereinbefore defined and the C_{2-4} -alkyl moiety of the C_{2-4} -alkyl-Y group is substituted in each case from position 2 by a 2-oxo-morpholino group optionally substituted by one or two C_{1-2} -alkyl groups,

25 a 4- $(C_{1-4}$ -alkyl)-piperazino- or 4- $(C_{1-4}$ -alkyl)-homopiperazino group substituted at a ring nitrogen atom by a 2-oxo-morpholino- C_{1-4} -alkyl group, wherein the 2-oxo-morpholino moiety may be substituted by one or two C_{1-2} -alkyl groups,

30 a piperazino or homopiperazino group substituted in the 4- position by a 2-oxo-morpholino- C_{1-4} -alkylene-CO group, wherein the 2-oxo-morpholino moiety may be substituted by one or two C_{1-2} -alkyl groups,

a piperazino or homopiperazino group substituted in the 4- position by a C₂₋₄-alkyl group, wherein the C₂₋₄-alkyl moiety is substituted in each case from position 2 by a 2-oxo-morpholino group optionally substituted by one or two C₁₋₂-alkyl groups,

- 5 a pyrrolidinyl or piperidinyl group substituted in the 1- position by the group R₇, by a R₆-C₁₋₄-alkyl-, R₆-CO-, R₆-C₁₋₄-alkylene-CO-, (R₅NR₇)-C₁₋₄-alkylene-CO-, R₇O-C₁₋₄-alkylene-CO-, R₇S-C₁₋₄-alkylene-CO-, R₇SO-C₁₋₄-alkylene-CO-, R₇SO₂-C₁₋₄-alkylene-CO- or 2-oxo-morpholino-C₁₋₄-alkylene-CO- group, wherein R₅ to R₇ are as hereinbefore defined and the 2-oxo-morpholino moiety may be substituted by one or
10 two C₁₋₂-alkyl groups,

- a pyrrolidinyl or piperidinyl group substituted in the 1- position by a C₂₋₄-alkyl group, wherein the C₂₋₄-alkyl moiety is substituted in each case from position 2 by a (R₅NR₇)-, R₇O-, R₇S-, R₇SO-, R₇SO₂- or 2-oxo-morpholino group, whilst R₅ and R₇ are as
15 hereinbefore defined and the 2-oxo-morpholino moiety may be substituted by one or two C₁₋₂-alkyl groups,

- a pyrrolidin-3-yl-NR₅, piperidin-3-yl-NR₅ or piperidin-4-yl-NR₅ group substituted at the ring nitrogen atom in each case by the group R₇, by a R₆-C₁₋₄-alkyl-, R₆-CO-, R₆-C₁₋₄-alkylene-CO-, (R₅NR₇)-C₁₋₄-alkylene-CO-, R₇O-C₁₋₄-alkylene-CO-, R₇S-C₁₋₄-alkylene-CO-, R₇SO-C₁₋₄-alkylene-CO-, R₇SO₂-C₁₋₄-alkylene-CO- or 2-oxo-morpholino-C₁₋₄-alkylene-CO- group, wherein R₅ to R₇ are as hereinbefore defined and the 2-oxo-morpholino moiety may be substituted by one or two C₁₋₂-alkyl groups,

- 25 a pyrrolidin-3-yl-NR₅, piperidin-3-yl-NR₅ or piperidin-4-yl-NR₅ group substituted in each case at the ring nitrogen atom by a C₂₋₄-alkyl group, wherein the C₂₋₄-alkyl moiety is substituted in each case from position 2 by a (R₅NR₇)-, R₇O-, R₇S-, R₇SO-, R₇SO₂- or 2-oxo-morpholino group, whilst R₅ and R₇ are as hereinbefore defined and the 2-oxo-morpholino moiety may be substituted by one or two C₁₋₂-alkyl groups,
30 a R₆-C₁₋₄-alkylene-NR₅ group in which R₅ and R₆ are as hereinbefore defined, or

a C₂₋₄-alkyl-NR₄ group, wherein the C₂₋₄-alkyl moiety is substituted in each case from position 2 by a (R₅NR₇)-, R₇O-, R₇S-, R₇SO-, R₇SO₂- or 2-oxo-morpholino group, whilst R₅ and R₇ are as hereinbefore defined and the 2-oxo-morpholino moiety may be substituted by one or two C₁₋₂-alkyl groups,

5

a 2-oxo-morpholin-4-yl group substituted by the group R₈ or by the group R₈ and a C₁₋₄-alkyl group, whilst

R₈ denotes a C₃₋₄-alkyl, hydroxy-C₁₋₄-alkyl, C₁₋₄-alkoxy-C₁₋₄-alkyl, di-(C₁₋₄-alkyl)-amino-C₁₋₄-alkyl, pyrrolidino-C₁₋₄-alkyl, piperidino-C₁₋₄-alkyl, morpholino-C₁₋₄-alkyl, 4-(C₁₋₄-alkyl)-piperazino-C₁₋₄-alkyl, C₁₋₄-alkylsulphanyl-C₁₋₄-alkyl, C₁₋₄-alkylsulphinyl-C₁₋₄-alkyl, C₁₋₄-alkylsulphonyl-C₁₋₄-alkyl, cyan-C₁₋₄-alkyl, C₁₋₄-alkoxycarbonyl-C₁₋₄-alkyl, aminocarbonyl-C₁₋₄-alkyl, C₁₋₄-alkyl-aminocarbonyl-C₁₋₄-alkyl, di-(C₁₋₄-alkyl)-aminocarbonyl-C₁₋₄-alkyl, pyrrolidinocarbonyl-C₁₋₄-alkyl, piperidinocarbonyl-C₁₋₄-alkyl, morpholinocarbonyl-C₁₋₄-alkyl or a 4-(C₁₋₄-alkyl)-piperazinocarbonyl-C₁₋₄-alkyl group,

15

a 2-oxo-morpholin-4-yl group substituted by two groups R₈, whilst R₈ is as hereinbefore defined and the two groups R₈ may be identical or different,

a 2-oxo-morpholin-4-yl group in which the two hydrogen atoms of a methylene group are replaced by a -(CH₂)_m-, -CH₂-Y-CH₂-, -CH₂-Y-CH₂-CH₂-, -CH₂CH₂-Y-CH₂CH₂- or -CH₂CH₂-Y-CH₂CH₂CH₂- bridge optionally substituted by one or two C₁₋₂-alkyl groups, whilst

25

m denotes the number 2, 3, 4, 5 or 6 and

Y denotes an oxygen or sulphur atom, a sulphinyl, sulphonyl or C₁₋₄-alkylimino group,

a 2-oxo-morpholin-4-yl group in which a hydrogen atom in the 5-position together with a hydrogen atom in the 6-position is replaced by a -(CH₂)_n-, -CH₂-Y-CH₂-, -CH₂-Y-CH₂CH₂- or -CH₂-CH₂-Y-CH₂- bridge, whilst

30

Y is as hereinbefore defined and
n denotes the number 2, 3 or 4,

whilst, unless otherwise stated, the aryl moieties mentioned in the definitions of the above-
5 mentioned groups denote a phenyl group which may be mono- or disubstituted by R₉,
whilst the substituents may be identical or different and

R₉ denotes a fluorine, chlorine, bromine or iodine atom, a C₁₋₂-alkyl, trifluoromethyl or C₁₋₂-alkoxy group, or
10

two groups R₉, if they are bound to adjacent carbon atoms, together denote a C₃₋₄-alkylene,
methylenedioxy or 1,3-butadien-1,4-ylene group,

or a tautomer or salt thereof.
15

2. A compound of the formula I according to claim 1, wherein

R_a denotes a hydrogen atom,
20

R_b denotes a 1-phenylethyl, 3-methylphenyl, 3-chlorophenyl, 3-bromophenyl or 3-chloro-
4-fluorophenyl group,

R_c denotes a hydrogen atom,
25

X denotes a nitrogen atom,

A denotes a 1,2-vinylene or ethynylene group,

30 B denotes a hydrogen atom,

C denotes an $-O-CH_2CH_2-$, $-O-CH_2CH_2CH_2-$ or $-O-CH_2CH_2CH_2CH_2-$ group, whilst the alkylene moiety in each case is linked to the group D, and

D denotes a piperidino group in which the two hydrogen atoms in the 4-position are
5 replaced by a $-CH_2-O-CO-CH_2-$,
 $-CH_2CH_2-O-CO-$, $-CH_2CH_2-O-CO-CH_2-$, $-O-CO-CH_2-NCH_3-CH_2-$ or $-O-CO-CH_2-O-CH_2-$ bridge,

10 a piperazino group in which a hydrogen atom in the 3-position together with the hydrogen atom in the 4-position are replaced by a $-CO-O-CH_2-CH_2-$ or $-CH_2-O-CO-CH_2-$ bridge, whilst in each case the left-hand ends of the above-mentioned bridges are bound to the 3-position of the piperazino ring,

15 a piperidino group which is substituted in the 4-position by a 2-oxo-morpholino or 2-oxo-morpholinomethyl group, whilst the 2-oxo-morpholino moiety may be substituted in each case by one or two methyl groups,

20 a piperazino group which is substituted in the 4-position by a 2-oxo-tetrahydrofuran-3-yl- or 2-oxo-tetrahydrofuran-4-yl group,

a piperidino group which is substituted in the 4-position by a R_6S group, whilst

R_6 denotes a 2-oxo-tetrahydrofuran-3-yl or 2-oxo-tetrahydrofuran-4-yl group,

25 a piperazino group which is substituted in the 4-position by a 2-oxo-tetrahydrofuranylmethyl or 2-oxo-tetrahydrofuranyl-carbonyl group,

a piperazino group which is substituted in the 4-position by a [2-(2-oxo-tetrahydrofuran-3-ylsulphenyl)ethyl] group,

30

a piperidin-4-yl group which is substituted in the 1-position by a 2-oxo-tetrahydrofuran-3-yl or 2-oxo-tetrahydrofuran-4-yl group,

5 a 2-oxo-morpholin-4-yl group which is substituted by a methoxymethyl or methoxyethyl group,

10 a 2-oxo-morpholin-4-yl group in which the two hydrogen atoms of a methylene group are replaced by a -CH₂CH₂CH₂CH₂-, -CH₂CH₂CH₂CH₂CH₂-, -CH₂-O-CH₂CH₂- or -CH₂CH₂-O-CH₂CH₂- bridge,
or a tautomer or salt thereof.

3. A compound of the formula I according to claim 1, wherein

15 R_a denotes a hydrogen atom,

R_b denotes a 1-phenylethyl or 3-chloro-4-fluorophenyl group,

20 R_c denotes a hydrogen atom,

X denotes a nitrogen atom,

A denotes a 1,2-vinylene group,

25 B denotes a hydrogen atom,

C denotes an -O-CH₂CH₂-, -O-CH₂CH₂CH₂- or -O-CH₂CH₂CH₂CH₂- group, whilst the alkylene moiety in each case is linked to the group D, and

30 D denotes a piperazino group which is substituted in the 4- position by a 2-oxo-tetrahydrofuran-4-yl or 2-oxo-tetrahydrofuran-5-ylcarbonyl group,

or a tautomer or salt thereof.

5 4. A compound selected from the group consisting of:

(1) 4-[(3-chloro-4-fluorophenyl)amino]-7-{3-[4-(2-oxo-tetrahydrofuran-4-yl)-piperazin-1-yl]-propyloxy}-6-[(vinylcarbonyl)amino]-quinazoline,

10 (2) 4-[(3-chloro-4-fluorophenyl)amino]-7-(2-{4-[(*S*)-(2-oxo-tetrahydrofuran-5-yl)carbonyl]-piperazin-1-yl}-ethoxy)-6-[(vinylcarbonyl)amino]-quinazoline,

(3) 4-[(*R*)-(1-phenylethyl)amino]-7-{2-[4-(2-oxo-tetrahydrofuran-4-yl)-piperazin-1-yl]-ethoxy}-6-[(vinylcarbonyl)amino]-quinazoline and

15 (4) 4-[(3-chloro-4-fluorophenyl)amino]-7-{2-[4-(2-oxo-tetrahydrofuran-4-yl)-piperazin-1-yl]-ethoxy}-6-[(vinylcarbonyl)amino]-quinazoline,

or a tautomer or salt thereof.

20

5. A physiologically acceptable salt of a compound according claim 1, 2, 3, or 4, formed with an inorganic or organic acid or base.

25 6. A pharmaceutical composition containing a compound according claim 1, 2, 3, or 4 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.

30 7. A method of treating a benign or malignant tumour, a disease of the respiratory tract or lungs, polyps, a disease of the gastro-intestinal tract, bile duct or gall bladder, a disease of the kidneys or of the skin, which comprises administering a therapeutically effective

amount of a compound according claim 1, 2, 3, or 4 or a pharmaceutically acceptable salt thereof.

099347531-082201